Ocugen
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Cell and Gene Therapy and Genome Editing
Ocugen is a clinical-stage biotechnology company focused on developing and commercializing transformative gene therapies to address blindness diseases and other serious conditions. Leveraging a novel modifier gene therapy platform, Ocugen is advancing a robust pipeline of one-time treatments designed to target multiple retinal diseases, including retinitis pigmentosa and geographic atrophy. The company is committed to bringing innovative therapies to patients with high unmet medical need.
Company HQ City:
Malvern
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2013
Lead Product in Development:
OCU400 (modifier gene therapy for retinitis pigmentosa)
CEO
Shankar Musunuri
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
3-4
Exchange
Nasdaq
Ticker
OCGN
When you expect your next catalyst update?
Q3 2026
What is your next catalyst (value inflection) update?
Initiation of rolling BLA submission for OCU400
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}